Rhythm Pharmaceuticals (RYTM) Competitors $101.04 +0.22 (+0.21%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM vs. BNTX, TEVA, GMAB, SMMT, ASND, VTRS, RDY, MRNA, ROIV, and QGENShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Its Competitors BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences QIAGEN BioNTech (NASDAQ:BNTX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Does the media favor BNTX or RYTM? In the previous week, BioNTech had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 9 mentions for BioNTech and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.09 beat BioNTech's score of 0.71 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate BNTX or RYTM? BioNTech currently has a consensus price target of $134.32, indicating a potential upside of 31.12%. Rhythm Pharmaceuticals has a consensus price target of $106.64, indicating a potential upside of 5.34%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.64Rhythm Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.94 Which has more volatility & risk, BNTX or RYTM? BioNTech has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500. Do institutionals and insiders believe in BNTX or RYTM? 15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is BNTX or RYTM more profitable? BioNTech has a net margin of -12.20% compared to Rhythm Pharmaceuticals' net margin of -117.13%. BioNTech's return on equity of -1.84% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-12.20% -1.84% -1.59% Rhythm Pharmaceuticals -117.13%-1,831.43%-48.33% Which has stronger earnings and valuation, BNTX or RYTM? Rhythm Pharmaceuticals has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$2.88B8.56-$719.92M-$1.60-64.02Rhythm Pharmaceuticals$156.29M43.02-$260.60M-$3.01-33.63 SummaryBioNTech beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.73B$3.34B$6.06B$10.43BDividend YieldN/A2.31%5.73%4.78%P/E Ratio-33.6622.2885.7927.08Price / Sales43.02417.97581.41185.05Price / CashN/A44.9825.7330.17Price / Book289.2510.3412.666.66Net Income-$260.60M-$52.31M$3.31B$276.03M7 Day Performance3.45%0.47%-0.49%-1.60%1 Month Performance5.21%13.71%8.62%5.93%1 Year Performance103.21%27.50%76.48%33.46% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals3.314 of 5 stars$101.04+0.2%$106.64+5.6%+102.4%$6.73B$156.29M-33.65140Positive NewsBNTXBioNTech2.151 of 5 stars$105.16-0.3%$134.56+28.0%-15.3%$25.36B$2.98B-65.726,772Analyst ForecastTEVATeva Pharmaceutical Industries3.234 of 5 stars$19.99-0.1%$25.57+27.9%+16.0%$22.95B$16.54B-124.9436,830Analyst UpgradeGMABGenmab A/S4.3001 of 5 stars$33.31-0.7%$40.80+22.5%+35.2%$21.55B$3.12B16.742,682Analyst RevisionHigh Trading VolumeSMMTSummit Therapeutics2.7669 of 5 stars$22.15+3.4%$31.29+41.2%+7.0%$15.92B$700K-21.93110ASNDAscendis Pharma A/S3.0241 of 5 stars$210.83+3.3%$244.36+15.9%+62.6%$12.59B$393.54M-40.861,017Analyst ForecastHigh Trading VolumeVTRSViatris1.8438 of 5 stars$10.13-0.6%$10.40+2.7%-14.4%$11.88B$14.74B-3.4932,000Positive NewsRDYDr. Reddy's Laboratories2.5109 of 5 stars$14.12-0.3%$16.95+20.0%-8.4%$11.82B$3.81B21.3927,811MRNAModerna4.2343 of 5 stars$27.54-3.3%$41.81+51.8%-54.0%$11.08B$3.24B-3.665,800Analyst ForecastROIVRoivant Sciences3.3469 of 5 stars$16.26+0.6%$19.94+22.6%+34.8%$11.04B$29.05M-23.23860QGENQIAGEN4.3745 of 5 stars$46.99+0.4%$49.40+5.1%+9.9%$10.40B$1.98B27.765,765Analyst Downgrade Related Companies and Tools Related Companies BioNTech Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Summit Therapeutics Competitors Ascendis Pharma A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Roivant Sciences Competitors QIAGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RYTM) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
